Mirtazapina Flas (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing serotonin 5‑HT2 and 5‑HT3 receptors while stimulating 5‑HT1 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mirtazapina Flas is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Mirtazapina Flas is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only if the potential benefit justifies the potential risk to the fetus. During breastfeeding, use only if the benefit to the mother outweighs possible exposure to the infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined antagonism of certain serotonin receptors and α2‑adrenergic blockade. This profile often results in pronounced sedative effects and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those prone to weight gain.

Mirtazapina Flas should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency.

Mirtazapina Flas is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe neutropenia, hepatotoxicity, seizures, and the emergence or worsening of suicidal thoughts, particularly during the early phase of treatment. Patients should be monitored closely for any signs of infection, liver dysfunction, or changes in mood.

Mirtazapina Flas is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently taking monoamine oxidase inhibitors (MAOIs) or who have taken an MAOI within the past 14 days. Caution is also advised for individuals with severe hepatic impairment.